Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMV-peptide vaccine
- Development stage
- Preclinical
- Lead developer
- Intravacc
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
OMV-peptide vaccine is an investigational **biologic vaccine** for COVID-19 being developed by Intravacc and EpiVax. It uses **bacterial outer membrane vesicles** as a nanoparticle delivery platform decorated with **synthetically generated multi-epitope peptides** derived from SARS-CoV-2, with epitope selection informed by immunoinformatics. The intended mechanism is to present coronavirus peptide epitopes to the immune system and induce a **T-cell-focused immune response** against **SARS-CoV-2** and potentially related beta-coronaviruses. Based on the provided information, the program was planned for pilot-scale manufacturing at Intravacc for clinical testing expected to begin in the fourth quarter of 2020.
- Other names
- OMV-peptide vaccine
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR5
Beyond the preview
Go deeper on OMV-peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMV-peptide vaccine.